Evaluation of the efficacy and safety of different cycles of neoadjuvant chemotherapy combined with immunotherapy in locally advanced esophageal squamous cell carcinoma: a multi-center, real-world study.
5 affiliations
- 1Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, No.12, Jiankang Road, Shijiazhuang, Hebei, 050000, China.
- 2Hebei Key Laboratory of Accurate Diagnosis and Comprehensive Treatment of Esophageal Cancer, Shijiazhuang, Hebei, 050000, China.
- 3Department of Thoracic Surgery, Handan Central Hospital, No. 59, North Congtai Road, Congtai District, Handan, Hebei, 056000, China.
- 4Department of Thoracic Surgery, Xingtai People's Hospital, No. 818, North Xiangdu Road, Xiangdu District, Xingtai, Hebei, 054000, China.
- 5Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, No.12, Jiankang Road, Shijiazhuang, Hebei, 050000, China. [email protected].
Abstract
Neoadjuvant chemotherapy combined with immunotherapy (nCIT) can improve radiologic and pathological responses in resectable, locally advanced esophageal squamous cell carcinoma (ESCC), yet the optimal number of preoperative cycles is unknown. We conducted a multicenter, real-world retrospective study of 284 patients with resectable ESCC treated between 2019 and 2024 who underwent radical esophagectomy after 1-4 cycles of nCIT. Patients were grouped as 1-2 versus 3-4 cycles and were additionally balanced using 1:1 propensity score matching. The primary endpoint was recurrence-free survival (RFS); secondary endpoints included objective response rate (ORR), pCR, adverse events (AEs), and postoperative complications. Before matching, ORR and pCR were higher with 3-4 cycles than with 1-2 cycles (ORR 85.6% vs. 75.1%; pCR 35% vs. 21%). After matching, these differences were not statistically significant (ORR 84.7% vs. 74.0%; pCR 31% vs. 22%). Median RFS was not reached in either group, and RFS rates were comparable after matching. The incidence and severity of AEs and postoperative complications were similar between groups, with leukopenia and pneumonia being most frequent, and no increase in severe toxicity with additional cycles. Subgroup analyses suggested potential heterogeneity of effect, with limited signals of benefit in earlier clinical stage and possible unfavorable outcomes in patients with nodal disease. Overall, 1-2 and 3-4 cycles of nCIT showed similar matched outcomes and safety.
Related
- Analysis of Laryngoscopic Image Differences in Different Responses to Neoadjuvant Immunotherapy Combined With Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma.
- Efficacy comparison of neoadjuvant chemotherapy, chemoradiotherapy, and chemoimmunotherapy in resectable esophageal squamous cell carcinoma: short- and long-term outcomes from a propensity score-matched analysis
- Immunotherapy plus chemotherapy versus immunotherapy alone in esophageal cancer: a real-world pharmacovigilance analysis of safety signals and fatal outcomes
- Neoadjuvant chemotherapy in locally advanced colon cancer: lessons from the NeoCol trial and the limits of anatomical risk stratification.
- Correlation of Axillary Nodal with Breast Response Following Neoadjuvant Chemotherapy in Early Breast Cancer
BibTeX
@article{lv2026evaluation,
title = {{Evaluation of the efficacy and safety of different cycles of neoadjuvant chemotherapy combined with immunotherapy in locally advanced esophageal squamous cell carcinoma: a multi-center, real-world study.}},
author = {Huilai Lv and Zuopeng Wang and Chunyong Su and Haijun Wang and Bisong Chen and Chunyue Gai and Yu Liu and Weilu Ding and Mingbo Wang and Kangbo Sun and Fan Zhang and Yonggang Zhu and Zhenhua Li and Ziqiang Tian},
journal = {World journal of surgical oncology},
year = {2026},
month = aug,
doi = {10.1186/s12957-026-04514-0},
url = {https://europepmc.org/article/MED/42968170},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Evaluation of the efficacy and safety of different cycles of neoadjuvant chemotherapy combined with immunotherapy in locally advanced esophageal squamous cell carcinoma: a multi-center, real-world study.
AU - Huilai Lv
AU - Zuopeng Wang
AU - Chunyong Su
AU - Haijun Wang
AU - Bisong Chen
AU - Chunyue Gai
AU - Yu Liu
AU - Weilu Ding
AU - Mingbo Wang
AU - Kangbo Sun
AU - Fan Zhang
AU - Yonggang Zhu
AU - Zhenhua Li
AU - Ziqiang Tian
PY - 2026
DA - 2026/08/03
JO - World journal of surgical oncology
DO - 10.1186/s12957-026-04514-0
UR - https://europepmc.org/article/MED/42968170
AB - Neoadjuvant chemotherapy combined with immunotherapy (nCIT) can improve radiologic and pathological responses in resectable, locally advanced esophageal squamous cell carcinoma (ESCC), yet the optimal number of preoperative cycles is unknown. We conducted a multicenter, real-world retrospective study of 284 patients with resectable ESCC treated between 2019 and 2024 who underwent radical esophagectomy after 1-4 cycles of nCIT. Patients were grouped as 1-2 versus 3-4 cycles and were additionally balanced using 1:1 propensity score matching. The primary endpoint was recurrence-free survival (RFS); secondary endpoints included objective response rate (ORR), pCR, adverse events (AEs), and postoperative complications. Before matching, ORR and pCR were higher with 3-4 cycles than with 1-2 cycles (ORR 85.6% vs. 75.1%; pCR 35% vs. 21%). After matching, these differences were not statistically significant (ORR 84.7% vs. 74.0%; pCR 31% vs. 22%). Median RFS was not reached in either group, and RFS rates were comparable after matching. The incidence and severity of AEs and postoperative complications were similar between groups, with leukopenia and pneumonia being most frequent, and no increase in severe toxicity with additional cycles. Subgroup analyses suggested potential heterogeneity of effect, with limited signals of benefit in earlier clinical stage and possible unfavorable outcomes in patients with nodal disease. Overall, 1-2 and 3-4 cycles of nCIT showed similar matched outcomes and safety.
SN - 1477-7819
ER -